You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • THU0176 Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Article info

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - anti-TNF therapy
THU0176 Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Authors

Citation

Kay J, Fleischmann R, Keystone E, et al
THU0176 Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Annals of the Rheumatic Diseases 2014;73:241-242.

Publication history

  • First published June 10, 2014.
Online issue publication 
February 20, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions